MACPAC Poised To Recommend Higher Rebates For Fast-Approval Drugs

By John Wilkerson / April 8, 2021 at 4:21 PM
Though they will not vote until Friday (April 9), nearly all congressional Medicaid adviser said Thursday that they support recommendations to hike Medicaid rebates for accelerated approval drugs and to impose additional inflationary rebates on companies that miss deadlines for post-market studies of those drugs. The draft recommendations by the Medicaid and CHIP Payment Access Commission leave it to Congress to determine how much rebates should be increased, whether some drugs should be excluded and at what point inflationary rebates...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.